Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Case Definition: 3-Quinuclidinyl Benzilate (BZ)

Clinical description

BZ toxicity, which might occur by inhalation, ingestion, or skin absorption, is an anticholinergic syndrome consisting of a combination of signs and symptoms that might include hallucinations; agitation; mydriasis (dilated pupils); blurred vision; dry, flushed skin; urinary retention; ileus; tachycardia; hypertension; and elevated temperature (>101ºF). The onset of incapacitation is dose-dependent. It might occur as early as 1 hour after exposure and continue up to 48 hours (1).

Laboratory criteria for diagnosis

  • Biologic: A case in which BZ is detected in urine (2), as determined by CDC.
  • Environmental: No method is available for detecting BZ in environmental samples.

Case classification

  • Suspected: A case in which a potentially exposed person is being evaluated by health-care workers or public health officials for poisoning by a particular chemical agent, but no specific credible threat exists.
  • Probable: A clinically compatible case in which a high index of suspicion (credible threat or patient history regarding location and time) exists for BZ exposure, or an epidemiologic link exists between this case and a laboratory-confirmed case.
  • Confirmed: A clinically compatible case in which laboratory tests on biologic samples have confirmed exposure.

The case can be confirmed if laboratory testing was not performed because either a predominant amount of clinical and nonspecific laboratory evidence of a particular chemical was present or a 100% certainty of the etiology of the agent is known.

Additional resources

  1. Ketchum JS, Sidell FR. Incapacitating agents. In: Zajtchuk R, Bellamy RF, eds. Textbook of military medicine: medical aspects of chemical and biologic warfare. Washington, DC: Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center ; 1997:287-305.
  2. Byrd GD, Paule RC, Sander LC, Sniegoski LT, White E 5th, Bausum HT. Determination of 3-quinuclidinyl benzilate (QNB) and its major metabolites in urine by isotope dilution gas chromatography/mass spectrometry. J Anal Toxicol 1992;16:182-7.
  • Page last reviewed February 14, 2013
  • Page last updated March 11, 2005
Contact Us:
Preparedness Month 2014

Ready.gov - Prepare. Plan. Stay Informed.
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO

A-Z Index

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #